银屑病关节炎结局指标的定义：GRAPPA-OMERACT工作组报告
Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group.
作者信息
Ogdie Alexis, de Wit Maarten, Callis Duffin Kristina, Campbell Willemina, Chau Jeffrey, Coates Laura C, Eder Lihi, Elmamoun Musaab, FitzGerald Oliver, Gladman Dafna D, Goel Niti, James Jana, Kalyoncu Umut, Latella John, Lindsay Chris, Mease Philip J, O'Sullivan Denis, Steinkoenig Ingrid, Strand Vibeke, Tillett William, Orbai Ana-Maria
机构信息
From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; K. Callis Duffin, MD, University of Utah; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; J. Chau, BA, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association; L.C. Coates, MBChB, PhD, Clinical Lecturer, NIHR, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; L. Eder, MD, PhD, Assistant Professor of Medicine, Women's College Research Institute, Women's College Hospital; M. Elmamoun, MBBS, MRCPI, Fellow, University of Toronto, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP( UK), Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; N. Goel, MD, Patient Research Partner, Vice President, Advisory Services, QuintilesIMS, and Adjunct Assistant Professor, Duke University School of Medicine; J. James, Patient Research Partner, Royal United Hospital; U. Kalyoncu, MD, Assistant Professor of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine; J. Latella, BS, MS, Patient Research Partner, and Board Member, International Dermatology Outcome Measurers; C. Lindsay, PharmD, Patient Research Partner; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine; W. Tillett, MBChB, PhD, Consultant Rheumatologist, Senior Lecturer, Royal United Hospital, and Pharmacy and Pharmacology, University of Bath; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Johns Hopkins University School of Medicine, and Director, Psoriatic Arthritis Program, Johns Hopkins Arthritis Center.
出版信息
J Rheumatol. 2017 May;44(5):697-700. doi: 10.3899/jrheum.170150.
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Core Set working group recently published the updated 2016 psoriatic arthritis (PsA) core domain set, a set of disease features that should be measured in all clinical trials. At the GRAPPA annual meeting in July 2016, the PsA working group presented the updated PsA core domain set endorsed by 90% of participants at OMERACT in May 2016 and drafted a roadmap for the development of the PsA core outcome measurement set. In this manuscript, we review the development process of the PsA core domain set and the ongoing and proposed work streams for development of a PsA core measurement set.
银屑病和银屑病关节炎研究与评估小组（GRAPPA）-风湿病结局评估（OMERACT）银屑病关节炎（PsA）核心领域工作组最近发布了2016年更新的银屑病关节炎（PsA）核心领域集，这是一组在所有临床试验中都应测量的疾病特征。在2016年7月的GRAPPA年会上，PsA工作组展示了2016年5月经OMERACT 90%参与者认可的更新后的PsA核心领域集，并起草了一份PsA核心结局测量集的开发路线图。在本手稿中，我们回顾了PsA核心领域集的开发过程以及PsA核心测量集开发中正在进行的和拟议的工作流程。
Zotero 插件